APA (7th ed.) Citation

Asselah, T., Moreno, C., Sarrazin, C., Gschwantler, M., Foster, G. R., Craxí, A., . . . Buti, M. (2016). An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). PLoS ONE, 11(7), 1. https://doi.org/10.1371/journal.pone.0158526

Chicago Style (17th ed.) Citation

Asselah, Tarik, et al. "An Open-Label Trial of 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)." PLoS ONE 11, no. 7 (2016): 1. https://doi.org/10.1371/journal.pone.0158526.

MLA (9th ed.) Citation

Asselah, Tarik, et al. "An Open-Label Trial of 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)." PLoS ONE, vol. 11, no. 7, 2016, p. 1, https://doi.org/10.1371/journal.pone.0158526.